このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

2026年7月17日 更新者:Servier

A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies

The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.

The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.

調査の概要

研究の種類

介入

入学 (推定)

64

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  • Investigator-assessed life expectancy of ≥ 3 months.
  • Able and willing to comply with requirements of the study protocol.
  • Documented genetic characterization of the disease as per local practice.
  • Clinical and laboratory thresholds:
  • Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
  • Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
  • Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
  • Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
  • Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.

Exclusion Criteria:

  • Known hypersensitivity to S241656, or Posaconazole (Part 1B).
  • Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
  • Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
  • Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
  • Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
  • Major surgery within 4 weeks.
  • Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
  • Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
  • Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
  • Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
  • History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
  • Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
  • Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
  • Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
  • Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
  • Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
  • Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
  • Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
  • All herbal preparations/supplements are prohibited.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part 1A: Dose Escalation
Tablets taken by mouth.
実験的:Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
Tablets taken by mouth.
Tablets taken by mouth

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1A and 1B) Number of Adverse Events (AEs)
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Severity of AEs
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Severity of SAEs
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of AEs
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of SAEs
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of changes in safety laboratory results
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of changes in physical examination
時間枠:Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose reductions due to AEs
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose interruptions due to AEs
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose delays due to AEs
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of study withdrawals due to AEs
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1B only) Maximum concentration (Cmax) of S241656
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Cmax of metabolite S243796
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Tmax of metabolite S243796
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Terminal half-life (t1/2) of S241656
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) t1/2 of metabolite S243796
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Area under the curve (AUC) of S241656
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) AUC of metabolite S243796
時間枠:Through Cycle 1 (28 days)
Through Cycle 1 (28 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
(Part 1A only) Cmax of S241656
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Cmax of metabolite S243796
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Tmax of S241656
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Tmax of metabolite S243796
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) AUC of S241656
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) AUC of metabolite S243796
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) t1/2 of S241656
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) t1/2 of metabolite S243796
時間枠:Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Complete remission (CR)
時間枠:Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
時間枠:Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
時間枠:Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
時間枠:Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Partial response (PR)
時間枠:Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Objective response (OR)
時間枠:Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Composite complete remission (CRc)
時間枠:Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
時間枠:Through end of treatment, up to approximately 4 years
In participants with AML or MDS/AML only
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of response (DOR)
時間枠:Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Time to response (TTR)
時間枠:Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Event free survival (EFS)
時間枠:Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Overall survival (OS)
時間枠:Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Marrow response
時間枠:Through end of treatment, up to approximately 4 years
In participants with CMML only
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
時間枠:Through end of treatment, up to approximately 4 years
In participants with CMML only
Through end of treatment, up to approximately 4 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月15日

一次修了 (推定)

2027年11月1日

研究の完了 (推定)

2030年9月30日

試験登録日

最初に提出

2026年7月8日

QC基準を満たした最初の提出物

2026年7月17日

最初の投稿 (実際)

2026年7月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月22日

QC基準を満たした最後の更新が送信されました

2026年7月17日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards
  • for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

IPD 共有時間枠

After Marketing Authorization in EEA or US if the study is used for the approval.

IPD 共有アクセス基準

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する